AtriCure Stock News

The Heart Defect Closure Devices is a closure device are used to close a defect or an opening between the right and left sides of the heart. Some of these birth defects are located in the wall between the upper

Prudential Financial Inc. raised its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 3.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,850 shares of the medical device companys stock after purchasing an additional 174 shares during the quarter. Prudential Financial Inc.s []

Morgan Stanley boosted its stake in AtriCure, Inc. (NASDAQ:ATRC) by 121.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 138,946 shares of the medical device companys stock after acquiring an additional 76,206 shares during the quarter. Morgan Stanley owned about []

Genesee Capital Advisors LLC bought a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 27,566 shares of the medical device companys stock, valued at approximately $1,917,000. Genesee Capital Advisors LLC owned 0.06% of []

AtriCure (NASDAQ:ATRC) was upgraded by research analysts at TheStreet from a c+ rating to a b rating in a note issued to investors on Tuesday, TheStreetRatingsTable reports. Other analysts have also issued research reports about the stock. Needham & Company LLC lifted their price objective on shares of AtriCure from $90.00 to $92.00 and gave []

TheStreet upgraded shares of AtriCure (NASDAQ:ATRC) from a c+ rating to a b rating in a research note published on Tuesday, TheStreetRatingsTable reports. Other research analysts have also issued reports about the company. Needham & Company LLC raised their price target on AtriCure from $90.00 to $92.00 and gave the stock a buy rating in […]

Analysts predict that AtriCure, Inc. (NASDAQ:ATRC) will announce $72.28 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for AtriCures earnings. The highest sales estimate is $74.00 million and the lowest is $71.10 million. AtriCure posted sales of $57.73 million during the same quarter last year, which would indicate a []

Zacks Investment Research downgraded shares of AtriCure (NASDAQ:ATRC) from a buy rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have []

AtriCure, Inc. (NASDAQ:ATRC) insider Tonya Austin sold 2,732 shares of the companys stock in a transaction dated Friday, November 12th. The shares were sold at an average price of $78.55, for a total transaction of $214,598.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Tonya Austin []

Data Bridge Market research presents the top quality and comprehensive Ablation technology research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This Ablation technology report deeply

Metropolitan Life Insurance Co NY lifted its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 101,233.3% in the second quarter, HoldingsChannel reports. The firm owned 12,160 shares of the medical device companys stock after buying an additional 12,148 shares during the quarter. Metropolitan Life Insurance Co NYs holdings in AtriCure were worth $965,000 as of its most []

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2021 Results - Earnings Call Transcript

AtriCure's (ATRC) CEO Mike Carrel on Q2 2021 Results - Earnings Call Transcript

AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that